Article date: December 2010
The European Medicines Agency’s Committee for Medicinal Products for Human Use has concluded that the benefits of the 4 fibrates—bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil—continue to outweigh the risks in the treatment of patients with blood-lipid disorders. However, healthcare professionals should not prescribe them to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.
Prescribing advice for fibrates can be found in the November 2007 issue of Drug Safety Update
Article citation: Drug Safety Update Dec 2010 vol 4 issue 5: S1.